Curated News
By: NewsRamp Editorial Staff
November 07, 2024
Pacylex Pharmaceuticals Welcomes Industry Veteran Michael Kamdar to Board of Directors
Discuss on Reddit
LinkedIn
Substack
Telegram
GithubTLDR
- Pacylex is the only company developing NMTis for hematologic and solid tumor cancers, giving a unique advantage in cancer treatment.
- Pacylex focuses on developing NMTis and ADC payloads for cancer treatment, with zelenirstat in Phase 2 clinical trials for AML.
- Pacylex's innovative therapies have the potential to significantly improve outcomes for oncology patients, bringing hope and progress to cancer treatment.
- Michael Kamdar, with vast experience in life sciences, joins Pacylex's Board of Directors, bringing expertise and strategic guidance to the company.
Impact - Why it Matters
This news highlights the strategic addition of Michael Kamdar to Pacylex's leadership team, signaling a new phase of growth and development for the company's groundbreaking cancer therapies. Kamdar's vast experience and track record in the life science industry will likely drive Pacylex's innovative programs towards clinical success, potentially revolutionizing cancer treatment.
Summary
Edmonton, Alberta, Canada November 7, 2024. Pacylex Pharmaceuticals Inc. (Pacylex) announced that seasoned life science executive Michael Kamdar has joined the Board of Directors. Kamdar's expertise in business deals and fundraising will advance Pacylex's innovative therapies for hematologic and solid tumor cancers. Company co-founder Dr. John Mackey transitions to Chief Medical Officer.
Source Statement
This curated news summary relied on this press release disributed by Reportable. Read the source press release here, Pacylex Pharmaceuticals Welcomes Industry Veteran Michael Kamdar to Board of Directors
